مباشر
Clinical OMICsSignatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care PathwayEndpoints NewsGoHealth files for bankruptcy, as Medicare Advantage insurers pull backAgilentHow Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics - simplywall.stBioPharma DiveTango data add to growing momentum for pancreatic cancer drugsBioWorldAppointments and advancements for June 8, 2026BioWorldFinancings for June 8, 2026BioWorldIn the clinic for June 8, 2026BioWorldOther news to note for June 8, 2026BioWorldRegulatory actions for June 8, 2026Thermo FisherThermo Fisher Scientific Introduces New Mass Spectrometry Platforms and AI Software - Clinical Lab ProductsBioPharma DiveIncyte to buy blood disorder drug in possibly $2B dealFierceBiotechClinical-stage cancer biotech Treeline sees path to public markets via reverse merger
BioWorld ٣٠ ديسمبر ٢٠٢٥

China accepts Hutchmed fanregratinib NDA on single phase II trial

China accepts Hutchmed fanregratinib NDA on single phase II trial

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.